Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus

Not Applicable

Completed

• Conditions: Type 2 Diabetes; Glucagon-like Peptide-1; Blood Flow; Blod Pressure; Human Physiology
• Interventions: Other: human glucagon-like peptide 1 (7-36)amide; Other: human glucagon-like peptide 1 (9-36)amide

• Registration Number: NCT01689051
• Lead Sponsor: University Hospital, Gentofte, Copenhagen

Brief Summary

Diabetes and high blood pressure are risk factors for developing heart disease. An increase in the number of diabetes patients is expected. This increases the number of patients with heart disease, and since the vast majority with diabetes die from heart disease, it is extremely important to investigate how these diseases can be prevented and treated.

Studies in animals have shown that intestinal hormone glucagon-like peptide-1 (GLP-1) can expand blood vessels, thus lowering blood pressure, but it is not known whether the effects is found in humans, which we will investigate.

Studies have also shown that GLP-1 lowers blood sugar, but it is unclear whether this is solely due to increased insulin production, weight loss associated with GLP-1 intake or GLP-1 has an effect on the muscles which increases the uptake of sugar. We investigate whether GLP-1 enhances the absorption of sugar in the leg.

The investigators also examines whether these effects are greater in people with diabetes then in healthy.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-03
• Study First Submitted: 2012-09-17
• Study First Submitted QC: 2012-09-17
• Study First Posted: 2012-09-20
• Primary Completion: 2013-04
• Study Completion: 2013-04
• Status Verified: 2014-01
• Last Update Submitted: 2014-01-30
• Last Update Posted: 2014-01-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

• Written informed consent
• T2DM according to WHO's criteria (only T2DM subjects)

Exclusion Criteria

• Anemia
• T1DM
• Severe liver or renal disease
• Severe heart disease
• Atrial fibrillation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Healthy subjects	human glucagon-like peptide 1 (7-36)amide	-
Healthy subjects	human glucagon-like peptide 1 (9-36)amide	-
Patients with type 2 diabetes	human glucagon-like peptide 1 (7-36)amide	-
Patients with type 2 diabetes	human glucagon-like peptide 1 (9-36)amide	-

Primary Outcome Measures

Name	Time	Method
Femoral artery blood flow

Secondary Outcome Measures

Name	Time	Method
Leg glucose uptake

Trial Locations

Locations (1)

Gentofte Hospital, Department of Cardiology; 🇩🇰 Hellerup, Denmark